Full text is available at the source.
Abstract
Concerns exist about a potential increased risk of non-arteritic ischemic optic neuropathy (NAION) linked to glucagon-like peptide 1 receptor agonist (GLP-1 RA) use.
- Inconsistent findings have been reported regarding the association between GLP-1 RA use and NAION risk.
- Variability in indications for drug use may contribute to differing outcomes across studies.
- Differences in comparator groups and follow-up periods could affect the assessment of risk.
- The study populations examined show considerable diversity, complicating the interpretation of results.
Simplified